EBOLA VIRUS: AN OVERVIEW DISEASE AND TREATMENT
Objective: Ebola virus disease (EVD) is a life-threatening viral disease. Death rate ranges between 30% and 90%, the first EVD outbreak was reported in the 1970s in Zaire. The global danger of this virus requires the need for producing effective vaccines and drugs is facing its outbreak threat. Even though there is no available commercial vaccine so far against EBOV, a few vaccine candidates are under evaluation to examine their therapeutic efficacy.
Methods: Based on many types of research, we present in our review the properties of the E. virus and EVD, the ongoing efforts to develop diagnostics, vaccines, and drugs for the cure of EVD.
Results: Despite the efforts of health organizations to study, reduce and treat Ebola infection, there are still many challenges including the early diagnosis and control of infection among people in addition to finding a suitable treatment and vaccine in addition to many social and medical reasons.
Conclusion: The good clinical knowledge about the disease and infection control is very important to fight against the outbreaks. Therefore, it is necessary to develop training programs to increase awareness about the diseases in affected areas.
2. Kourtis AP, Appelgren K, Chevalier MS, McElroy A. Ebola virus disease: Focus on children. Pediatr Infect Dis J 2015;34:893-7.
3. Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC. Ebola virus disease: A review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med 2014;72:442-8.
4. Kimura H, Tsukagoshi H, Ryo A, Oda Y, Kawabata T, Majima T, et al. Ebola virus disease: A literature review. J Coast Life Med 2015;3:85-90.
5. World Health Organization. High-level Meeting on the Ebola Outbreak in the Democratic Republic of the Congo Affirms Support for Government-led Response and UN System-wide Approach; 2019.
6. Jean-Jacques Muyembe Tamfum: A life’s work on ebola. Bull World Health Organ 2018;96:804-5.
7. Kaner J, Schaack S. Understanding ebola: The 2014 epidemic. Globalization and Health 2016;12:53.
8. World Health Organization, Ebola virus Disease; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease.
9. Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus disease. Lancet 2019;393:936-48.
10. Majid MU, Tahir MS, Ali Q, Rao AQ, Rashid B, Ali A, et al. Nature and history of Ebola virus: An overview. Arch Neurosci 2016;3:e35027.
11. Yobsan D, Walkite F, Nesradin Y. Ebola virus and its public health significance: A review. J Vet Sci Res 2018;3:165.
12. Abouelwafa M, George JJ. Ebola virus and its Potential Drug Targets, International Science Symposium on Recent Trends in Science and Technology February 26 and 27; 2017.
13. Kumar S, Kumari R, Pandey R, Sharma V. Ebola virus disease: Biology, diagnosis, treatment and prevention of epidemics. Proc Indian Natl Sci Acad 2017;83:103-49.
14. Parasuraman P, Suresh RS, Perumal P. Searching antiviral drugs for Ebola virus from phytoconstituents of Azadirachta indica: Application of molecular modelling studies. Asian J Pharm Clin Res 2017;10:254-7.
15. Madariaga MG. Ebola virus disease: A perspective for the United States. Am J Med 2015;128:682-91.
16. Cantoni D, Rossman JS. Ebolaviruses: New roles for old proteins. PLoS Negl Trop Dis 2018;12:e0006349.
17. Munjita SM, Kwenda G. Descriptive analysis of bola virus proteins: Towards development of effective therapeuticsand vaccines. Br Microbiol Res J 2015;8:457-79.
18. Avaliable from: https://www.fineartamerica.com/featured/ebola-virus-illustration-evan-oto.html?product=art-print.
19. Centers for Disease Control and Prevention, Ebola virus Disease EVD; 2018. Available from: http://www.cdc.gov/vhf/ebola.
20. Ruparelia C, Curless M, Trexler P, Black M. Prevention and Control of Ebola Virus Disease in Health Care Facilities with Limited Resources, Reference Manual; 2015.
21. Fischer WA, Brown J, Wohl DA, Loftis AJ, Tozay S, Reeves E, et al. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute Ebola virus infection. Open Forum Infect Dis 2017;4:ofx155.
22. Boon SD, Marston BJ, Nyenswah TG, Jambai A, Barry M, Keita S, et al. Ebola virus infection associated with transmission from survivors. Emerg Infect Dis J 2019;25:2019.
23. Mustafa M, Yusof MI, Kassim M, Jeffree MS, Illzam EM, Sharifa AM. Ebola virus disease, management, and prevention. IOSR J Dent Med Sci 2016;15:142-8.
24. Available from: https://www.cdc.gov/vhf/ebola/resources/virus-ecology. html.
25. Yu DS, Weng TH, Wu XX, Wang FXC, Lu XY, Wu HB, et al. The lifecycle of the Ebola virus in host cells. Oncotarget 2017;8:55750-9.
26. Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 2016;55:907-23.
27. Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palù G, et al. Ebola virus entry: From molecular characterization to drug discovery. Viruses 2019;11:E274.
28. Available from: https://www.viralzone.expasy.org/5016.
29. Kaushal S, Kumari S. A review on Ebola virus, the diseases, causes and management. Int Res J Pharm 2017;8:1-8.
30. Khalafallah MT, Aboshady OA, Moawed SA, Ramadan MS. Ebola virus disease: Essential clinical knowledge. Avicenna J Med 2017;7:96-102.
31. Moghadam SR, Omidi N, Bayrami S, Moghadam SJ, Seyedalinaghi S. Ebola viral disease: Review literature. Asian Pac J Trop Biomed 2015;5:260-7.
32. Broadhurst MJ, Brooks TJ, Pollock NR. Diagnosis of Ebola virus disease: Past, present, and future. Clin Microbiol Rev 2016;29:773-93.
33. Martínez MJ, Salim AM, Hurtado JC, Kilgore PE. Ebola virus infection: Overview and update on prevention and treatment. Infect Dis Ther 2015;4:365-90.
34. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A, et al. Ebola virus disease in West Africa clinical manifestations and management. N Engl J Med 2014;371:2054-7.
35. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc 2014;11:1341-50.
36. Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, Olango J, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003;9:1430-7.
37. Dyary HO, Rahman HS, Othman HH, Abdullah R, Chartrand MS. Advancements in the therapy of Ebola virus disease. Pediatr Infect Dis 2016;1:22.
38. Joffe S. Evaluating novel therapies during the ebola epidemic. JAMA 2014;312:1299-300.
39. World Health Organization. Essential Medicines and Health Products; 2019. Available from: https://www.who.int/medicines/ebola-treatment/ ebola_drug_clinicaltrials/en.
40. Espeland EM, Tsai CW, Larsen J, Disbrow GL. Safeguarding against ebola: Vaccines and therapeutics to be stockpiled for future outbreaks. PLoS Negl Trop Dis 2018;12:e0006275.
41. World Health Organization. Essential Medicines and Health Products; 2019. Available from: https://www.who.int/medicines/ebola-treatment/ ebola_vaccine_clinicaltrials/en.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.